Navigation Links
Mesa Labs Reports Higher Quarterly Sales and Earnings
Date:2/11/2008

LAKEWOOD, Colo., Feb. 11 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: MLAB) today reported significantly higher sales and earnings for both its fiscal third quarter and nine months ended December 31, 2007.

Highlights:

-- Third quarter revenue increases 13%

-- Third quarter net income increases 37%

-- Third quarter diluted EPS increases 36%

For the third quarter of fiscal 2008, net sales increased 13 percent to $4,614,000 from $4,095,000 in the same quarter last year. Net income for the quarter increased 37 percent to $1,121,000 or $.34 per diluted share compared to $818,000 or $.25 per diluted share one year ago.

For the first nine months of fiscal 2008, net sales increased 15 percent to $13,768,000 from $11,956,000 in the same period last year. Net income for the first nine months increased 36 percent to $3,415,000 or $1.04 per diluted share compared to $2,520,000 or $.78 per share one year ago.

"The third quarter of fiscal 2008 was another good quarter for Mesa," said John J. Sullivan, President and Chief Operating Officer. "We had good revenue growth and exceptional earnings growth, due largely to our improved gross margins this year. The third quarter is traditionally a weaker quarter for Mesa, but this year we had exceptional growth in the quarter for our DataTrace product line. This was due partially to a very weak Q3 for DataTrace last year and partially to the exceptional performance of our U.S. sales team. DataTrace, has very good momentum going into the last quarter of fiscal 2008. While our other two core product lines, Raven and Medical, experienced relatively little growth in the third quarter, we see these lines recovering in the last quarter of the year to the order rate we saw in the first half," continued John Sullivan. "Looking ahead, we have a number of important initiatives that should foster both short term and long term growth. These include executing a significant new product introduction in DataTrace, increasing our R&D effort in all product lines, and implementing efficiency improvements in all of our operations. As always, we will undertake these initiatives in a cost effective manner to allow for continued earnings growth."

During the third quarter and first nine months of fiscal 2008, sales of the Company's medical products and services were unchanged and increased nine percent, respectively, compared to the prior year periods. For the quarter, small increases of shipments in the meter product line and parts and service were off-set by a decrease in Echo Reprocessors which were discontinued earlier in the fiscal year. The increase for the nine month period was due chiefly to higher sales of the Company's dialysate meters and standard solution products.

During the third quarter and first nine months of fiscal 2008, sales of DataTrace data logger products increased compared to the prior year. For the quarter, DataTrace sales increased 46 percent compared to the same period last year, while sales increased 17 percent for the nine month period compared to the same period last year. The increase in DataTrace sales during the quarter reflects higher shipments of Micropack III temperature and humidity units and an increase in rental revenues. The increase for the nine month period is attributable chiefly to higher Micropack III temperature units and higher service revenues.

Third quarter sales of Raven biological indicator products increased two percent compared to the prior year period. The Raven biological indicator products were acquired on May 4, 2006. For this reason, sales of the company's Raven biological indicator products benefited from an extra five weeks of sales for the current nine month period when compared to the prior year period and were up 27 percent. While order volumes remained strong during the recent quarter, shipments did not keep up with orders due to heavier order volumes late in the quarter and some disruption to manufacturing and shipments due to facility upgrades that were performed the last week of the quarter.

Profitability for the third quarter and nine month periods of fiscal 2008 was up compared to the prior fiscal year due chiefly to the increase in revenues and a gain in our gross margin percentage. For the quarter, net income increased 37 percent and exceeded sales growth which was 13 percent for the quarter. For the first nine month period, net income increased 36 percent and exceeded sales growth which was 15 percent for the period. Net income also benefited from a slightly lower tax rate due to the impact of the Raven acquisition on our overall tax rate.

During the second half of October 2007, we began documentation of our compliance with Section 404 of the Sarbanes-Oxley Act. We are using an outside consulting firm to assist us with this work and expect to incur expenses for this project of at least $100,000 by the end of April 2008. By the end of the third fiscal quarter almost all documentation review was complete and testing is currently scheduled for March and April. Through December 31, 2007, the company had incurred approximately $44,000 of the consulting fees associated with this project.

During the first nine months of fiscal 2008, the Company repurchased 35,848 shares of our common stock under a previously announced buyback plan for approximately $779,000. In addition, the Company has a remaining commitment of approximately $340,000 for automation of certain manufacturing processes for its Raven line of biological indicators.

Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.

This news release contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form-10KSB for the year ended March 31, 2007 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.

FINANCIAL SUMMARY

STATEMENT OF EARNINGS

(Unaudited)

Quarter Ended Nine Months Ended

December 31 December 31

2007 2006 2007 2006

Net Sales $4,614,000 $4,095,000 $13,768,000 $11,956,000

Cost of Goods 1,527,000 1,633,000 4,494,000 4,427,000

Gross Profit 3,087,000 2,462,000 9,274,000 7,529,000

Operating Expense 1,399,000 1,202,000 4,150,000 3,675,000

Operating Income 1,688,000 1,260,000 5,124,000 3,854,000

Other (Income) &

Expense (54,000) (36,000) (150,000) (104,000)

Earnings Before

Taxes 1,742,000 1,296,000 5,274,000 3,958,000

Income Taxes 621,000 478,000 1,859,000 1,438,000

Net Income $1,121,000 $818,000 $3,415,000 $2,520,000

Earnings Per Share

(Basic) $.35 $.26 $1.08 $.80

Earnings Per Share

(Diluted) $.34 $.25 $1.04 $.78

Average Shares

(Basic) 3,165,000 3,177,000 3,168,000 3,156,000

Average Shares

(Diluted) 3,292,000 3,273,000 3,285,000 3,232,000

BALANCE SHEETS (Unaudited)

Dec. 31 March 31

2007 2007

Cash and Short-

term Investments $5,186,000 $3,346,000

Other Current

Assets 7,654,000 7,496,000

Total Current

Assets 12,840,000 10,842,000

Property and

Equipment 3,621,000 3,521,000

Other Assets 7,614,000 7,991,000

Total Assets $24,075,000 $22,354,000

Liabilities $1,252,000 $1,631,000

Stockholders'

Equity 22,823,000 20,723,000

Total Liabilities

and Equity $24,075,000 $22,354,000


'/>"/>
SOURCE Mesa Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
2. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
3. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
4. Neurobiological Technologies Reports Second Quarter Financial Results
5. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
6. Bioniche Reports Fiscal 2008 Second Quarter
7. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
8. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
9. Hot Flashes Not Always to Blame for Sleep Problems in Menopausal Women, Reports the Harvard Womens Health Watch
10. Pathology Reports Good for Breast Cancer Studies
11. American Pacific Reports Revenue Increase of 34% and Net Income of $2.9 Million for Fiscal 2008 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: